Cowen & Co. analyst Phil Nadeau downgrades Tricida (NASDAQ:TCDA) from Outperform to Market Perform.
Johnson & Johnson Q1 Earnings Tops Wall Street Estimates On Strong Medical Devices Sales, Boosts Annual Outlook
Johnson & Johnson reports Q1 results: adjusted EPS $2.71 (up 12.4% Y/Y), sales $21.38B (up 2.3% Y/Y). Explore pharma giant's robust performance, including strong growth in Innovative Medicine and medical devices sales.
